Nameofjournal:WorldJournalofGastroenterologyESPSManuscriptNO:566Columns:BRIEFARTICLESQuadrupletherapyforeradicationofHelicobacterpyloriMaHJetal.EradicateHelicobacterpyloristrategyHai-JunMa,激n-L诅ngWangHai-JunMaz激n-LiangWang,DepartmentofGastroenterology,theFirstAffiliatedHosp让alofHenanUniversityofScienceandTechnology,Luoyang471003,HenanProvince,ChinaAuthorcontributions:MaHJcontributedtocollectthesubjectandpreparethemanuscript;WangJLcontributedtoconceiveanddesignthetopic,reviewandanalyzetheliterature.Correspondenceto:激n-LiangWang,Professor,DepartmentofGastroenterology,theFirstAffiliatedHosp让alofHenanUniversityofScienceandTechnology,NO.24of激nghuaroad,Luoyang471003,HenanProvince,China.wangjinliang3008@163Telephone:+86-379-64830750Fax:+86-379-64807159Received:September12012Revised:December18,2012Accepted:December22,2012Publishedonline:AbstractAIM:Toinvestigaterabeprazole,amoxicillin,levofloxacinandfurazolidonequadrupletherapyfortheeradicationofHelicobacterpylori(H.pylori)infection.METHODS:147patientsweredividedintoanexperimentaltreatmentgroup(78)andastandardtripletreatmentgroup(69).Thetreatmentgroupreceivedrabeprazole20mg,amoxicillin1.0g,levofloxacin0.2g,furazolidone0.1g,twicedaily.Thestandardtripletreatmentgroupwasgivenomeprazole20mg,amoxicillin1.0g,clarithromycin0.5gztwicedailyregimen.RESULTS:Onemonthaftertreatment,13CureabreathtestwasdonetodetectH.pylori,theeradicationratewithper-protocolanalysiswas94.3%intheexperimentaltreatmentgroupand73%inthestandardtripletreatmentgroup(P<0.05),w让hintentiontotestanalysiswere86%and67%inthetwogroupsrespectively.Sideeffectswerefoundin34patients,includingmilddizziness,nausea,d诅rrheaandincreasedbowelmovement.Noneofthe11patientsneededtreatmentfortheirsideeffects.CONCLUSION:Rabeprazole,amoxicillin,levofloxacinandfurazolidonequadrupletherapyisasafemethodforeradicationofH.pyloriwithhighefficacyandgoodtolerability.©2012Baishideng.Allrightsreserved.Keywords:Rabeprazole;Amoxicillin;Levofloxacin;Furazolidone;HelicobacterpyloriMaHJ,WangJL.QuadrupletherapyforeradicationofHelicobacterpyloriAvailableom:DOI:INTRODUCTIONHelicobacterpylori(H.pylori)iscloselyrelatedtogastrointestinaldisease・Itisthemainpathogenicfactorsofchronicgastritisandpepticulcer,itisalsotheirdtiatingfactorforgastriccancerandgastricmucosa-associatedtissuelymphoid卩】・Abilitytoreliablyeradicatethepathogenisimportantformanagingthesediseases"].Inclinicalpractice,fortheeffectivetreatmentoftheabovediseases,theeradicationofH.pylorihasbeenaresearchfulfocus.Currently,theworldwidestandtripletherapyconsistsofaprotonpumpinhib让ors(PPI)orbismuth,amoxicillinandmetronidazoleorclarithromycin.However,withtheextensiveuseofantibioticsandtheirregularityofthetreatment,thereisincreasinglyhigherH.pyloriresistance,especiallyresistanttometronidazoleandclarithromycin.Theeffectivenessofzzlegacytripletherapy"whichwasrecommendedbyMaastrichtIIICon-sensusReportprovidesdisappointinglylowtreatmentsuccess(i.e.,below80%)intheworld⑹.ThedifficultyoferadicationofH.pyloriisincreasing.TheconsensusoftheThirdNationalLushanmeetingheldatLushanMountainin激angxiinAugust2007statesthereishigherH.pyloriresistanttometronidazoleandclarithromycin,butlowresistanttofurazolidone,tetracyclineandquinolones,thereforetheeffectsofthetheseantibioticsarerelativelyhigh,soitmaybeusedastheirdtialchoiceoftreatment.Inourstudy,rabeprazole,...